Background This study aimed to investigate clinical characteristics, laboratory indexes, treatment regimens, and short‐term outcomes of severe and critical coronavirus disease 2019 (COVID‐19) patients. Methods One hundred and sixty one consecutive severe and critical COVID‐19 patients admitted in intensive care unit (ICU) were retrospectively reviewed in this multicenter study. Demographic features, medical histories, clinical symptoms, lung computerized tomography (CT) findings, and laboratory indexes on admission were collected. Post‐admission complications, treatment regimens, and clinical outcomes were also documented. Results The mean age was 59.38 ± 16.54 years, with 104 (64.60%) males and 57 (35.40%) females. Hypertension (44 [27.33%]) and diabetes were the most common medical histories. Fever (127 [78.88%]) and dry cough (111 [68.94%]) were the most common symptoms. Blood routine indexes, hepatic and renal function indexes, and inflammation indexes were commonly abnormal. Acute respiratory distress syndrome (ARDS) was the most common post‐admission complication (69 [42.86%]), followed by electrolyte disorders (48 [29.81%]), multiple organ dysfunction (MODS) (37 [22.98%]), and hypoproteinemia (36 [22.36%]). The most commonly used antiviral drug was lopinavir/ritonavir tablet. 50 (31.06%) patients died, while 78 (48.45%) patients healed and discharged, and the last 33 (20.50%) patients remained in hospital. Besides, the mean hospital stay of deaths was 21.66 ± 11.18 days, while the mean hospital stay of discharged patients was 18.42 ± 12.77 days. Furthermore, ARDS (P < .001) and MODS (P = .008) correlated with increased mortality rate. Conclusion Severe and critical COVID‐19 presents with high mortality rate, and occurrence of ARDS or MODS greatly increases its mortality risk.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. AbstractObjective: The present study aimed to investigate the correlation of katanin P80 expression with clinicopathological features and survival profile in non-small-cell lung cancer (NSCLC) patients. Methods:Totally, 398 NSCLC patients treated by pulmonary resection were enrolled and their tumor specimens were collected to determine katanin P80 expression by immunohistochemistry (IHC) assay. Clinical data were collected at diagnosis, and survival data including disease-free survival (DFS) and overall survival (OS) were assessed after treatment.Results: There were 195 (49.0%) patients with katanin P80 high expression and 203 (51.0%) patients with katanin P80 low expression, respectively. Meanwhile, katanin P80 high expression was associated with larger tumor size (P = .001), lymph node (LYN) metastasis (P = .005), and advanced TNM stage (P = .001). As for survival data, katanin P80 high expression was correlated with reduced DFS (P < .001) and OS (P < .001). And forward stepwise multivariate Cox's regression revealed that katanin P80 high expression was an independent predictor for decreased DFS (P < .001) and OS (P < .001). Besides, further analysis indicated that DFS (P < .001) and OS (P < .001) were the shortest in patients with katanin P80 high+++ expression, followed by patients with katanin P80 high++ expression and then those with katanin P80 high + expression and katanin P80 low expression. Conclusion:Katanin P80 correlates with larger tumor size, LYN metastasis, and advanced TNM stage, and serves as a potential biomarker for predicting poor survival in NSCLC patients. K E Y W O R D S disease-free survival, Katanin P80, non-small-cell lung cancer, overall survival, tumor features How to cite this article: Ye Q, Zhang M, Yin Y. Katanin P80 correlates with larger tumor size, lymph node metastasis, and advanced TNM stage and predicts poor prognosis in nonsmall-cell lung cancer patients. J Clin Lab Anal.

Background The pandemic of coronavirus disease 2019 (COVID-19) has become a global public health problem. It is important for clinical physicians to differentiate COVID-19 from other respiratory infectious diseases caused by viruses, such as human adenovirus. Subjects and Methods This was a retrospective observational study. We analyzed and compared the clinical manifestations, laboratory findings and radiological features of two independent cohorts of patients diagnosed with either COVID-19 (n=36) or adenovirus pneumonia (n=18). Results COVID-19 did not show a preference in males or females, whereas 94.4% of patients with adenovirus pneumonia were males. Fever and cough were common in both COVID-19 and adenovirus pneumonia. But the median maximal body temperature of the adenovirus pneumonia cohort was significantly higher than in COVID-19 ( P <0.001). Furthermore, 77.8% of patients with adenovirus pneumonia had a productive cough versus only 13.9% of COVID-19 patients ( P <0.001). Compared with adenovirus pneumonia, constitutional symptoms were less common in COVID-19, including headache (16.7% vs 38.9%, P =0.072), sore throat (8.3% vs 27.8%, P =0.058), myalgia (8.3% vs 61.1%, P <0.001) and diarrhea (8.3% vs 44.4%, P =0.002). Furthermore, patients with COVID-19 were less likely to develop respiratory failure (8.3% vs 83.3%, P <0.001) and showed less prominent laboratory abnormalities, including lymphocytopenia (61.1% vs 88.9%, P =0.035), thrombocytopenia (2.8% vs 61.1%, P <0.001), elevated procalcitonin (2.8% vs 77.8%, P <0.001) and elevated C-reactive protein (36.1% vs 100%, P <0.001). Besides, a higher percentage of patients with adenovirus pneumonia showed elevated transaminase, myocardial enzymes, creatinine and D-dimer compared with COVID-19 patients. On chest CT, the COVID-19 cohort was characterized by peripherally distributed ground-glass opacity and patchy shadowing, while the adenovirus pneumonia cohort frequently presented with consolidation and pleural effusion. Conclusion There were many differences between patients diagnosed with COVID-19 and those with adenovirus pneumonia in their clinical, laboratory and radiological characteristics. Compared with adenovirus pneumonia, COVID-19 patients tended to show a lower severity of illness.

To evaluate the chest computed tomography (CT) findings of patients with Corona Virus Disease 2019 (COVID‐19) on admission to hospital. And then correlate CT pulmonary infiltrates involvement with the findings of emphysema. We analyzed the different infiltrates of COVID‐19 pneumonia using emphysema as the grade of pneumonia. We applied open‐source assisted software (3D Slicer) to model the lungs and lesions of 66 patients with COVID‐19, which were retrospectively included. we divided the 66 COVID‐19 patients into the following two groups: (A) 12 patients with less than 10% emphysema in the low‐attenuation area less than −950 Hounsfield units (%LAA‐950), (B) 54 patients with greater than or equal to 10% emphysema in %LAA‐950. Imaging findings were assessed retrospectively by two authors and then pulmonary infiltrates and emphysema volumes were measured on CT using 3D Slicer software. Differences between pulmonary infiltrates, emphysema, Collapsed, affected of patients with CT findings were assessed by Kruskal–Wallis and Wilcoxon test, respectively. Statistical significance was set at p < 0.05. The left lung (A) affected left lung 20.00/affected right lung 18.50, (B) affected left lung 13.00/affected right lung 11.50 was most frequently involved region in COVID‐19. In addition, collapsed left lung, (A) collapsed left lung 4.95/collapsed right lung 4.65, (B) collapsed left lung 3.65/collapsed right lung 3.15 was also more severe than the right one. There were significant differences between the Group A and Group B in terms of the percentage of CT involvement in each lung region (p < 0.05), except for the inflated affected total lung (p = 0.152). The median percentage of collapsed left lung in the Group A was 20.00 (14.00–30.00), right lung was 18.50 (13.00–30.25) and the total was 19.00 (13.00–30.00), while the median percentage of collapsed left lung in the Group B was 13.00 (10.00–14.75), right lung was 11.50 (10.00–15.00) and the total was 12.50 (10.00–15.00). The percentage of affected left lung is an independent predictor of emphysema in COVID‐19 patients. We need to focus on the left lung of the patient as it is more affected. The people with lower levels of emphysema may have more collapsed segments. The more collapsed segments may lead to more serious clinical feature.